Deals channel feed – Endpoints News

Deals channel feed

Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive

8 years ago

Sanofi finally manages to close on a buyout – but it’s not a game changer

8 years ago

Gilead buy Vertex? A golden oldie in the M&A buzz circuit gets fresh air time

8 years ago

Buyout Buzz: Sanofi, Gilead rumors keep the fire burning under a boiling Tesaro buyout story

8 years ago

Tesaro is reportedly on the auction block, but who can afford it?

8 years ago

It’s all quite satisfactory, merci: Sanofi chairman Serge Weinberg shrugs off growing calls for an M&A deal

9 years ago

So what’s holding back Pfizer and Gilead from the really big M&A deals we’ve all been waiting for?

9 years ago

The top 9 overseas accounts in biopharma hold $133B in M&A firepower

9 years ago

Politics, pricing controversy, tax reform and steep valuations conspire to confuse Sanofi’s M&A strategy

9 years ago

Sucampo bags rare disease player Vtesse in $200M buyout agreement

9 years ago

Astellas swoops in on a mid-stage drug for hot flashes in $860M biotech buyout deal

9 years ago

Report — Sanofi close to bagging Flexion in a looming $1B-plus buyout, shares rocket up

9 years ago

Texas biotech executes a reverse merger with a battered Threshold

9 years ago

Meacham’s manifesto to Gilead: It’s time to do something dramatic — buy, bag or burn

9 years ago

Global Blood Therapeutics shares spike on buzz about a potential Novo buyout

9 years ago

Defending its prize franchise, Vertex forks over $160M cash to grab Concert’s simplified version of Kalydeco

9 years ago

Otsuka Pharma snags a late-stage ADHD drug in $250M Neurovance buyout

9 years ago

How could you make a Bristol-Myers takeover work without shredding a $5B R&D division?

9 years ago

Buyout buzz swells for the giant Bristol-Myers after Carl Icahn makes an entrance, stage left

9 years ago

Sage CEO’s M&A chatter sparks a spike, and an awkward correction

9 years ago

Behind the scenes of J&J’s $30B Actelion buyout: Walkouts, Sanofi’s blunder and a $230M sweetener

9 years ago

The next PARP M&A deal? Tesaro shares surge on latest buzz about a buyout

9 years ago

Amgen rips off its $10B M&A cap, looking for deals “large and small”

9 years ago

Celgene scoops up freshman autoimmune startup Delinia in $775M buyout

9 years ago

First page Previous page 112 113 114115116 117 Next page Last page